Catecholaminergic Polymorphic Ventricular Tachycardia - Looking to the Future.

Area of Science:

• Cardiology
• Genetics
• Electrophysiology

Background:

• Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, inherited cardiac disorder.
• It is characterized by polymorphic or bidirectional ventricular tachycardia triggered by adrenergic stress, often leading to syncope or sudden cardiac death.
• Genetic mutations, primarily in ryanodine and calsequestrin channels, underlie most CPVT cases, though a significant portion remain genotype-unknown.

Purpose of the Study:

• To review the current understanding of CPVT diagnosis, treatment, and the critical need for improved risk stratification.
• To highlight the importance of integrating clinical and genetic data for personalized patient management.

Main Methods:

• Review of existing literature on CPVT genetics, diagnosis, and therapeutic strategies.
• Discussion of diagnostic criteria including ECG findings, exercise/stress testing, and genetic testing.
• Exploration of current and emerging treatment options, including pharmacologic and interventional approaches.

Main Results:

• Diagnosis relies on identifying ventricular arrhythmias during stress in individuals with structurally normal hearts and normal resting ECGs.
• Effective treatments include beta-blockers, flecainide, ICD implantation, and left cardiac sympathetic denervation.
• Genetic testing is crucial but has limitations, with approximately one-third of cases remaining genetically undefined.

Conclusions:

• Accurate risk stratification is paramount for optimizing CPVT patient treatment.
• Establishing large patient registries and bio-banks is vital for collecting comprehensive clinical and genetic data.
• Developing a robust risk stratification score integrating both data types will enable more targeted and effective therapeutic strategies.